# eGenesis

eGenesis is an other based in Cambridge, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Cambridge, United States
- **Region:** North America
- **Address:** Cambridge, MA, United States
- **Assets under management:** Undisclosed
- **Website:** egenesisbio.com
- **LinkedIn:** https://www.linkedin.com/company/egenesis

## Regulatory record

- **Reports private funds:** No

## About

At eGenesis, we envision a world where transplantation is accessible to all. We develop safe and effective human-compatible organs for transplantation.

## Sectors

- Biotech
- Gene Editing
- Transplant Medicine

## People

- Mike Curtis — President & Chief Executive Officer
- Jennifer Bergheiser — Chief Business Officer
- Elizabeth Roberts — Chief People Officer
- Jay Barth — Chief Medical Officer
- Susan Low — SVP, Development
- Wenning Qin — SVP, Innovation

## Questions

### What investment stage does eGenesis represent?

eGenesis is a development-stage biotechnology company. It has received FDA clearance for a Phase 1/2/3 clinical trial for its engineered kidney, EGEN-2784, which places it in late clinical development. The company has not publicly disclosed its funding rounds or valuation.

### Who leads eGenesis?

Mike Curtis, Ph.D., serves as President and CEO. The leadership team includes Chief Business Officer Jennifer Bergheiser, Chief Medical Officer Jay Barth, M.D., Chief People Officer Elizabeth Roberts, SVP of Development Susan Low, Ph.D., and SVP of Innovation Wenning Qin, Ph.D.

### What is eGenesis's core technology?

eGenesis uses multiplex gene editing to modify porcine genomes, addressing three classes of edits: removal of retroviral elements, immunologic compatibility, and molecular compatibility. This integrated platform aims to create donor pigs whose organs are safe and effective for human transplantation.

### Has eGenesis received regulatory approval for clinical trials?

Yes. The U.S. Food and Drug Administration cleared its Investigational New Drug application to initiate a Phase 1/2/3 trial for EGEN-2784, a genetically engineered pig kidney, in patients with end-stage kidney disease (per the firm's website).

### What progress has eGenesis made with human patients?

As of March 2026, eGenesis's gene-edited pig kidneys had been implanted in human patients, with reported clinical promise (per Fast Company, March 2026). This follows a January 2026 CNN report on a patient who received an experimental pig kidney and later a human organ.

### Where is eGenesis headquartered?

eGenesis is based in Cambridge, Massachusetts, United States. No additional office locations have been disclosed.

## Related profiles

- [Impact Angel Network](https://altss.com/profile/impact-angel-network)
- [Voxel](https://altss.com/profile/voxel)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/egenesis

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology